This article is more than 5 years old. Information may no longer be current.

Glaucoma patients have poor treatment adherence rates, study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FLORENCE, Italy — Patients who use prostaglandins to control IOP have poor compliance rates, according to a pharmacy claims study. Gail F. Schwartz, MD, presented the results here during the European Glaucoma Society meeting.

Drug records from 2,503 patients were included for analysis, said Dr. Schwartz. Of these, 477 (19%) had discontinued and restarted their initial drug by day 180, the final follow-up day. An additional 40 patients (2%) had discontinued use of their initial drug and later restarted on prostaglandin, Dr. Schwartz said.

Of the 1,986 remaining patients, 879 (35%) persisted with treatment to the end, 280 (11%) discontinued use of the prostaglandin and switched to another class of drug and 827 (33%) failed to restart any treatment.